Get a free sample of Aspergillosis Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Aspergillosis Treatment Market
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Aspergillosis Treatment Market Size
Aspergillosis treatment market size was valued at around USD 3.8 billion in 2023 and is estimated to grow at 4.3% CAGR from 2024 to 2032. Aspergillosis treatment, where aspergillosis is a group of fungal infections caused by aspergillus species, commonly found indoors and outdoors. It ranges from mild to severe and predominantly affects individuals with weakened immune systems or existing lung conditions.
The rising incidence of aspergillosis is a significant driver for the market. For instance, according to the Centers for Disease Control and Prevention (CDC’s) report indicates that approximately 2.5% of adults diagnosed with asthma also suffer from allergic bronchopulmonary aspergillosis (ABPA), totaling around 4.8 million individuals globally. Among these ABPA cases, an estimated 400,000 people additionally contend with chronic pulmonary aspergillosis (CPA), in 2024.
Therefore, this underscores the growing importance of addressing fungal infections, particularly in individuals with underlying respiratory conditions, which necessitates heightened awareness, research, and treatment options. Furthermore, growing awareness of fungal infections and development of new antifungal agents, are driving factors for the market growth.
Who are the leading aspergillosis treatment industry players?
Abbott Laboratories, Astellas Pharma Inc., Astra Zeneca PLC, Basilea Pharmaceutica Ltd., Bayer AG, Endo International plc, F2G, GSK plc, Johnson & Johnson, Merck & Co., Inc., and Mayne Pharma Group Limited, among others
What is the size of the aspergillosis treatment market?
Global aspergillosis treatment industry was valued at USD 3.8 billion in 2023 and is anticipated to register 4.3% CAGR between 2024 and 2032 due to the rising incidence of aspergillosis and growing awareness of fungal infections.
Why is the demand for aspergillosis treatment rising in hospital pharmacies?
The hospital pharmacies segment in the market is forecasted to reach USD 3 billion by 2032 due to comprehensive antifungal inventories and specialized pharmacists optimizing therapy for complex infections like aspergillosis.
Why is the use antifungal drugs rising in aspergillosis treatment?
The antifungal drugs segment in the aspergillosis treatment market accounted for USD 2.4 billion in 2023 due to the efficacy of azoles, echinocandins, and polyenes in treating aspergillosis and their versatile formulations for tailored therapies.